Earlier this week, Motley Fool health-care bureau chief Brenton Flynn discussed Johnson & Johnson's (JNJ -0.63%) failed attempt to get its blood thinner Xarelto approved by the FDA for a lucrative new treatment area. In this video, Brenton tells us about one headwind that could potentially impact sales of blood thinners across the board. If a device coming out from Boston Scientific (BSX -0.28%) to prevent blood clots due to atrial fibrillation receives approval in the U.S., it could be worth half a billion dollars for the company, and could slightly weigh on blood thinner sales, if successful. Brenton tells us which companies could be affected by this under-the-radar trend.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Bad News for Blood Thinners?
NYSE: JNJ
Johnson & Johnson

Could this be a headwind for blood thinner sales that investors missed?
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned




*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.